194 related articles for article (PubMed ID: 23674207)
1. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.
van Rij CM; Lütje S; Frielink C; Sharkey RM; Goldenberg DM; Franssen GM; McBride WJ; Rossi EA; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1377-83. PubMed ID: 23674207
[TBL] [Abstract][Full Text] [Related]
2. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
Cancer Biother Radiopharm; 2014 Oct; 29(8):323-9. PubMed ID: 25226447
[TBL] [Abstract][Full Text] [Related]
3. Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.
van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Franssen GM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
Mol Imaging Biol; 2015 Feb; 17(1):94-101. PubMed ID: 25060065
[TBL] [Abstract][Full Text] [Related]
4. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
[TBL] [Abstract][Full Text] [Related]
5. A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers.
Sharkey RM; van Rij CM; Karacay H; Rossi EA; Frielink C; Regino C; Cardillo TM; McBride WJ; Chang CH; Boerman OC; Goldenberg DM
J Nucl Med; 2012 Oct; 53(10):1625-32. PubMed ID: 22952342
[TBL] [Abstract][Full Text] [Related]
6. Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer.
Schoffelen R; van der Graaf WT; Sharkey RM; Franssen GM; McBride WJ; Chang CH; Bos DL; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2012 Dec; 53(12):1926-32. PubMed ID: 23081995
[TBL] [Abstract][Full Text] [Related]
7. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
[TBL] [Abstract][Full Text] [Related]
8. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
Schoffelen R; Woliner-van der Weg W; Visser EP; Goldenberg DM; Sharkey RM; McBride WJ; Chang CH; Rossi EA; van der Graaf WT; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1593-602. PubMed ID: 24643780
[TBL] [Abstract][Full Text] [Related]
9. Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer.
Lütje S; Rijpkema M; Goldenberg DM; van Rij CM; Sharkey RM; McBride WJ; Franssen GM; Frielink C; Helfrich W; Oyen WJ; Boerman OC
Cancer Res; 2014 Nov; 74(21):6216-23. PubMed ID: 25252911
[TBL] [Abstract][Full Text] [Related]
10. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
11. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
[TBL] [Abstract][Full Text] [Related]
12. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
Schoffelen R; Sharkey RM; Goldenberg DM; Franssen G; McBride WJ; Rossi EA; Chang CH; Laverman P; Disselhorst JA; Eek A; van der Graaf WT; Oyen WJ; Boerman OC
Mol Cancer Ther; 2010 Apr; 9(4):1019-27. PubMed ID: 20354120
[TBL] [Abstract][Full Text] [Related]
13. Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?
Rousseau C; Kraeber-Bodéré F; Barbet J; Chatal JF
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1373-6. PubMed ID: 23760632
[No Abstract] [Full Text] [Related]
14. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results.
Schoffelen R; Boerman OC; Goldenberg DM; Sharkey RM; van Herpen CM; Franssen GM; McBride WJ; Chang CH; Rossi EA; van der Graaf WT; Oyen WJ
Br J Cancer; 2013 Aug; 109(4):934-42. PubMed ID: 23860529
[TBL] [Abstract][Full Text] [Related]
15. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.
Cheal SM; Xu H; Guo HF; Lee SG; Punzalan B; Chalasani S; Fung EK; Jungbluth A; Zanzonico PB; Carrasquillo JA; O'Donoghue J; Smith-Jones PM; Wittrup KD; Cheung NV; Larson SM
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):925-937. PubMed ID: 26596724
[TBL] [Abstract][Full Text] [Related]
16. A universal pretargeting system for cancer detection and therapy using bispecific antibody.
Sharkey RM; McBride WJ; Karacay H; Chang K; Griffiths GL; Hansen HJ; Goldenberg DM
Cancer Res; 2003 Jan; 63(2):354-63. PubMed ID: 12543788
[TBL] [Abstract][Full Text] [Related]
17. Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga.
Karacay H; Sharkey RM; McBride WJ; Rossi EA; Chang CH; Goldenberg DM
J Nucl Med; 2011 Apr; 52(4):555-9. PubMed ID: 21421724
[TBL] [Abstract][Full Text] [Related]
18. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
[TBL] [Abstract][Full Text] [Related]
19. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.
Griffiths GL; Chang CH; McBride WJ; Rossi EA; Sheerin A; Tejada GR; Karacay H; Sharkey RM; Horak ID; Hansen HJ; Goldenberg DM
J Nucl Med; 2004 Jan; 45(1):30-9. PubMed ID: 14734668
[TBL] [Abstract][Full Text] [Related]
20. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]